Efficacy and safety of homoharringtonine plus cytarabine and aclarubicin for patients with myelodysplastic syndrome-RAEB

  • Authors:
    • Feng Xiao
    • Ying Li
    • Weilai Xu
    • Liangshun You
    • Chunmei Yang
    • Hui Liu
    • Wenbin Qian
  • View Affiliations

  • Published online on: November 5, 2015     https://doi.org/10.3892/ol.2015.3876
  • Pages: 355-359
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to evaluate the treatment outcome of homoharringtonine, cytarabine (AraC) and aclarubicin combination therapy as induction treatment for myelodysplastic syndromes‑refractory anemia with excess blasts (MDS‑RAEB). A total of 24 patients with MDS‑RAEB who were aged between 18 and 66 years were treated with homoharringtonine, AraC and aclarubicin (HAA regimen). The HAA regimen consisted of homoharringtonine (2 mg/m2 intramuscularly twice daily, days 1‑3), AraC (75 mg/m2 injected subcutaneously twice daily, days 1‑7) and aclarubicin (12 mg/m2, days 1‑7). The overall response rate was 79% with a complete remission rate of 58.3% and partial remission rate of 20.7%. There was no evidence of early mortality in this group of patients. The median overall survival (OS) was 36.2 months (95% confidence interval, 24.6‑47.4 months), and the estimated three year overall survival rate was 45.8%. In conclusion, HAA combination therapy is a suitable induction regimen for patients with MDS‑RAEB, which may improve the outcome for de novo higher‑risk MDS patients, particularly of those with favorable and intermediate cytogenetics.
View Figures
View References

Related Articles

Journal Cover

January-2016
Volume 11 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Xiao F, Li Y, Xu W, You L, Yang C, Liu H and Qian W: Efficacy and safety of homoharringtonine plus cytarabine and aclarubicin for patients with myelodysplastic syndrome-RAEB. Oncol Lett 11: 355-359, 2016
APA
Xiao, F., Li, Y., Xu, W., You, L., Yang, C., Liu, H., & Qian, W. (2016). Efficacy and safety of homoharringtonine plus cytarabine and aclarubicin for patients with myelodysplastic syndrome-RAEB. Oncology Letters, 11, 355-359. https://doi.org/10.3892/ol.2015.3876
MLA
Xiao, F., Li, Y., Xu, W., You, L., Yang, C., Liu, H., Qian, W."Efficacy and safety of homoharringtonine plus cytarabine and aclarubicin for patients with myelodysplastic syndrome-RAEB". Oncology Letters 11.1 (2016): 355-359.
Chicago
Xiao, F., Li, Y., Xu, W., You, L., Yang, C., Liu, H., Qian, W."Efficacy and safety of homoharringtonine plus cytarabine and aclarubicin for patients with myelodysplastic syndrome-RAEB". Oncology Letters 11, no. 1 (2016): 355-359. https://doi.org/10.3892/ol.2015.3876